SCHEMBL3150604

SCHEMBL3150604

CNc1nccc(CN)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT3 Q9Y243 2/20 0.40
AURKA O14965 1/20 0.38
TTK P33981 1/20 0.38
AURKB Q96GD4 1/20 0.38
INCENP Q9NQS7 1/20 0.38
PDPK1 O15530 1/20 0.37
DYRK1A Q13627 1/20 0.36
AOC1 P19801 2/20 0.35
AOC3 Q16853 2/20 0.35
FLT3 P36888 2/20 0.35
MAPK13 O15264 1/20 0.35
RAF1 P04049 1/20 0.35
MAPK9 P45984 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
MAPK14 Q16539 1/20 0.35
PDE6D O43924 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.33
ROCK1 Q13464 1/20 0.33
PIK3C3 Q8NEB9 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL805468 0.82 PDE6D (0.38) AKT3AURKATTKAURKBINCENP
SCHEMBL1787663 0.80 HDAC1 (0.40) AKT3AURKATTKAURKBINCENP
SCHEMBL20379433 0.80 CCR1 (0.39) AKT3AURKATTKAURKBINCENP
Hydrochloric Acid SCHEMBL30157701 0.79 PDPK1 (0.41) PDPK1AOC1AOC3
SCHEMBL28112390 0.78 PDE6D (0.39) AKT3AURKATTKAURKBINCENP
SCHEMBL15360315 0.77 NOS3 (0.42) AKT3AURKATTKAURKBINCENP
SCHEMBL12499912 0.77 RXRA (0.35) AKT3AURKATTKAURKBINCENP
SCHEMBL15360316 0.77 CYP1A2 (0.41) AKT3AURKATTKAURKBINCENP
SCHEMBL12996146 0.77 SYK (0.36) AKT3AURKATTKAURKBINCENP
SCHEMBL29499180 0.76 PDE6D (0.35) AKT3AURKATTKAURKBINCENP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537084-B1 SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF AMGEN INC (US) 2013-08-21 EP disclosed
US-7687643-B2 Process for preparing 3,3-dimethylindolines AMGEN INC. (US) 2010-03-30 US disclosed
EP-1664027-B1 SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2009-12-30 EP disclosed
US-7320992-B2 Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use AMGEN INC. (US) 2008-01-22 US disclosed
US-20050261313-A1 Substituted alkylamine derivatives and methods of use AMGEN INC. 2005-11-24 US disclosed
EP-1537084-A1 SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF Amgen Inc. (US) 2005-06-08 EP disclosed
US-20050054670-A1 Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use AMGEN INC. 2005-03-10 US disclosed
WO-2004007458-A1 SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF AMGEN INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054670-A1 Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use VHL, DPYD, UGT1A1 AKT3 1403/4885AURKA 4162/4885TTK 4172/4885
US-20050261313-A1 Substituted alkylamine derivatives and methods of use NAT1, PIGO, AADAC AKT3 2423/4885AURKA 2147/4885TTK 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.